One of oncology's biggest challenges is that the same treatment can work well for some patients but fail completely in others. A study published in Nature Communications, by a multidisciplinary team ...

One of oncology's biggest challenges is that the same treatment can work well for some patients but fail completely in others.

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that preclinical data from its IL ...

One of oncology's biggest challenges is that the same treatment can work well for some patients but fail completely in others. A study published in ...

Researchers at the Earlham Institute, the University of Edinburgh and Heriot-Watt University analyzed gut cells to understand ...

As inflamed regions of the gut form scar tissue, the space within the gut lumen becomes smaller and more restricted, leading ...

This article explores how multiomics integration, imaging, and bioinformatics are advancing biomarker discovery, revealing ...

BostonGene, developer of the leading AI foundation model for tumor and the immune biology, today announced it has been honored as the Innovator of the Year at the 2025 Life Sciences Times Vanguard ...

This article explores how advanced immune imaging technologies enable real-time visualization of immune responses, improving ...

CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...

A key Alzheimer’s drug has finally revealed its secret. Researchers discovered that lecanemab works by activating the brain’s immune cells—but only through a specific part of the antibody called the ...

IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. For decades, the "gut-kidney axis" hypothesis has suggested that the ...